Companies with technology platforms that address only a tiny part of the drug discovery process risk becoming optional or redundant accessories.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Papadopoulos, S. Business models in biotech. Nat Biotechnol 18 (Suppl 10), IT3–IT4 (2000). https://doi.org/10.1038/80065
Issue Date:
DOI: https://doi.org/10.1038/80065